Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Sensitive Epigenetic-Based PCR Test Could Detect Difficult-To-Diagnose Breast Tumor

By LabMedica International staff writers
Posted on 05 Feb 2024

Phyllodes tumors, which make up less than 1% of breast tumors, present a diagnostic challenge due to their microscopic resemblance to other breast tumor types. While the majority of phyllodes tumors are benign, about 10% are malignant. Getting an accurate diagnosis is key to ensuring the right treatment is given, as a misdiagnosis can lead to inappropriate or delayed care. Typically, tumor diagnosis is based on the pathological examination of cellular patterns. Now, scientists have found the epigenetic ‘signature’ of phyllodes tumors, paving the way for the development of a sensitive epigenetic-based PCR test to detect this hard-to-diagnose breast tumor that could be routinely used in pathology laboratories.

Scientists at the Garvan Institute of Medical Research (NSW, Australia) have identified new DNA markers based on epigenetics that could provide additional diagnostic information for phyllodes tumors. Epigenetic alterations involve changes in gene activity levels without modifying the DNA sequence itself and can be influenced by environmental factors. One common epigenetic process is DNA methylation, where methyl groups attach to DNA segments, altering gene expression. In their study of samples from 33 patients, the research team observed a distinct DNA methylation pattern in phyllodes tumors, distinguishing them from other cancers. They also developed an algorithm that successfully reclassified samples that had initially been misdiagnosed. This advancement in understanding may lead to more accurate diagnoses and better patient outcomes.

“Disruption to epigenetic processes, such as DNA methylation patterns, is a recognized hallmark of cancer and can vary significantly between cancer types, allowing a unique cancer forensic signature,” said Professor Susan Clark, co-senior author and Head of the Cancer Epigenetics Lab at Garvan. “Harnessing the power of cutting-edge epigenetic technologies, like Digital Droplet PCR, our next step will be devising a sensitive epigenetic-based PCR test to detect phyllodes tumors that could be routinely used in pathology laboratories.”

Related Links:
Garvan Institute of Medical Research

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.